Abstract
Objective: Copeptin comprises the C-terminal part of the Arginine vasopressin (AVP) precursor, is co-secreted with AVP and is a stable surrogate marker for AVP release, making it much easier to measure. Elevated levels of serum copeptin in both cardiovascular and renal diseases were known but the amount and predictive value of copeptin in the unity of these diseases is unknown.
 Methods: A study composed equally divided five groups, total of 150 adult patients. Group I and group II composed study groups which included the patients of chronic ischemic heart (CHID) and chronic kidney diseases (CKD) respectively. Control groups such as group III, IV and V included only patients of CHID or CKD. Copeptin, hs-CRP and pro-BNP levels were analyzed in all patients and their relationship with adverse outcomes were evaluated.
 Results: Serum levels of copeptin, hs-CRP and pro-BNP were higher in patients of study groups than patients of control groups and it was found statistically meaningful (p
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
